A method for preparing coumarin compounds and their use in neuroprotection

By designing and synthesizing novel coumarin compounds to activate the Nrf2 signaling pathway, the problem of poor antioxidant stress activation in the treatment of neurodegenerative diseases in the prior art is solved, and significant protection of nerve cells and Nrf2 activation is achieved. The improvement of function provides new potential for neuroprotective drug development.

CN116675663BActive Publication Date: 2024-11-08LANZHOU JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310653018.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-05
Publication Date
2024-11-08
Estimated Expiration
2043-06-05

AI Technical Summary

Technical Problem

The existing methods for treating neurodegenerative diseases are difficult to effectively activate the Keap1/Nrf2/ARE signaling pathway, resulting in poor treatment of antioxidant stress, and the existing Nrf2 activators have problems with toxicity or limited activation effects.

Method used

A series of novel structural coumarin compounds were designed and synthesized, prepared by specific chemical reaction processes, using these compounds to activate Nrf2 and used as candidate molecules for neuroprotective drugs, demonstrating significant protective effects and comparison of PC12 cells. Strong Nrf2 activation function.

Benefits of technology

These new coumarin compounds have shown significant neuroprotective activity in in vitro experiments, have strong cell protection effects, and far exceed the activation ability of traditional Nrf2 activators, providing a new direction for the development of neuroprotective drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116675663B_ABST
    Figure CN116675663B_ABST
Patent Text Reader

Abstract

The present invention relates to a new coumarin compound as shown in formula (I), as well as a preparation method of the compound and its use in the preparation of neuroprotective small molecule drugs. The general chemical formula of the compound is as shown in formula (I). The preparation method of the compound in formula (I) is obtained by the reaction of 2-(trimethylsilyl)phenyl trifluoromethanesulfonate and 2-(arylsulfonyl)acetonitrile. Neuroprotective activity experiments have shown that the compounds described in the present invention have good neuroprotective activity, and the neuroprotective activity of most compounds is higher than that of the control drug resveratrol, and can be used as a leading molecule for the development of neuroprotective and neurodegenerative disease drugs. The preparation process of the present invention is simple, the raw materials are cheap and easy to obtain, and the product purity is high. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new coumarin compound, a preparation method of the compound and the use of the compound in preparing a neuroprotective drug, belonging to the field of medicine. Background Art

[0002] Reactive oxygen species (ROS) are byproducts produced by aerobic organisms during aerobic metabolism. They can be free radicals, such as hydroxyl radicals, superoxide anion radicals, etc., which are characterized by having unpaired electrons; they can also be non-free radicals with high oxidation potentials such as hydrogen peroxide and singlet oxygen (Nature Chemical Biology, 2011, 7 (8): 504-511.). Under physiological conditions, the powerful antioxidant system of cells can maintain the generation and removal of ROS to achieve a dynamic balance. At this time, ROS, as a regulator of signal molecules or transcription factors, participates in physiological processes such as cell differentiation, proliferation and apoptosis. However, due to the influence of some internal or external factors, such as aging, genetic variation, radiation, etc., the redox homeostasis in the body may be destroyed, resulting in rapid accumulation of ROS, thereby inducing the occurrence of oxidative stress. Oxidative stress can directly or indirectly oxidatively modify the chemical structures of nucleic acids, proteins, lipids and sugars, ultimately causing loss of function or changes in biological macromolecules, and these results have been shown to be closely related to the occurrence and development of neurodegenerative diseases (Nature Reviews Drug Discovery, 2004, 3 (3): 205-214.). Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc., are caused by the continuous degeneration or even death of specific neurons. As mentioned above, oxidative stress is precisely one of the important factors causing neuronal dysfunction and death. At present, the introduction of exogenous antioxidants or the enhancement of the body's endogenous antioxidant defense system are the two major ways to treat oxidative stress-related diseases, of which the latter is more widely concerned by researchers because it is regulated at the transcriptional level and is more persistent than the former (Medicinal Research Reviews, 2012, 32 (4): 687-726.).

[0003] The Keap1 / Nrf2 / ARE signaling pathway is one of the most important intrinsic mechanisms for the body to resist oxidative stress. The nuclear transcription factor Nrf2 is responsible for regulating a series of cell protection and detoxification genes. Keap1 is a cytoplasmic inhibitory protein that can inhibit the activity of Nrf2. In redox homeostasis, Keap1 binds to the ETGE and DLG sequences of Nrf2, thereby promoting the ubiquitination-proteasome degradation of Nrf2 in the cytoplasm. Under oxidative stress conditions, the key cysteine ​​residues on Keap1 are modified, resulting in a decrease in the activity of the E3 ubiquitin ligase that connects the Keap1-Cul3 complex. Nrf2 in the cytoplasm will enter the nucleus and bind to the small Maf protein on the ARE, thereby initiating the transcription and expression of a variety of downstream antioxidant genes / detoxification genes, which can achieve the effect of cell protection. Therefore, activating the Nrf2 / ARE signaling pathway is an effective method for treating neurodegenerative diseases (Nature Reviews Drug Discovery, 2019, 18(4): 295-317; Medicinal Research Reviews, 2021, 41(2): 785-802.). Currently, dimethyl fumarate (trade name Tecfidera) and oleanolic acid derivatives (trade name Skyclarys) are already used as Nrf2 activators for the treatment of multiple sclerosis and Friedreich's ataxia, respectively.

[0004] Natural products are the source of innovation for new drug discovery. Natural coumarins have a wide range of biological activities, and they themselves have certain antioxidant and neuroprotective activities (Mini Reviews in Medicinal Chemistry, 2009, 9(11): 1262-1271.). Combining the structural characteristics of current Nrf2 activators, we designed and synthesized 20 novel small molecule compounds containing coumarin skeletons (see the instructions). Figure 1 The protective effects of these compounds on PC12 cells and the activation effects on Nrf2 were tested. Summary of the invention

[0005] The purpose of the present invention is to provide a novel coumarin derivative capable of activating Nrf2. At the same time, another purpose of the present invention is to provide a preparation method of this novel compound and its use as a candidate molecule of neuroprotective drugs in neurodegenerative diseases.

[0006] The series of new coumarin derivatives described in the present invention have the following Figure 2 Chemical structures shown:

[0007] Structural formula instructions attached Figure 2wherein the substituent R is selected from phenyl, 4-fluorophenyl, 3-fluorophenyl, 2-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 4-methylphenyl, 3-methylphenyl, 1-naphthyl, 2-naphthyl, and 2-thienyl.

[0008] The preparation method of the present invention is as follows: Figure 1 The chemical reaction shown is carried out:

[0009] The coumarin compounds of this novel structure described in the present invention (attached to the specification) Figure 2 The preparation method of the compound is to use 2-(arylsulfonyl)acetonitrile and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate with different substituents as raw materials, N,N-dimethylformamide (DMF) as reactant and solvent, potassium fluoride (KF) as base, react under heating conditions for about 6 hours, detect by thin layer chromatography, and purify and separate by column chromatography (elution system is petroleum ether: ethyl acetate) to obtain the target compound.

[0010] The best preparation method of the novel coumarin compounds of the present invention is to carry out the following steps:

[0011] ① Preparation method of intermediate 2-(arylsulfonyl)acetonitrile: using sulfonyl chloride with different substituents (0.71mmol) as raw material, taking appropriate amount of water as reaction solvent, adding sodium sulfite (0.18g, 1.42mmol) and sodium bicarbonate (0.12g, 1.42mmol) in sequence, then heating to 100℃ and reflux for 2 hours. After stopping the reaction, the reaction solution is concentrated under reduced pressure, and then the solid is directly subjected to the next step of reaction without purification, tetrahydrofuran is added under stirring, and chloroacetonitrile (0.05g, 0.71mmol) is added dropwise under argon protection, and the temperature is gradually raised to 60℃ to start the reaction. After the reaction is completed by thin layer chromatography monitoring, the reaction is stopped. The reaction solution is concentrated under reduced pressure, washed with water, and filtered to obtain the intermediate 2-(arylsulfonyl)acetonitrile.

[0012] ② Take the intermediate 2-(arylsulfonyl)acetonitrile (0.55mmol), potassium fluoride (KF) (0.13g, 2.23mmol), and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (0.33g, 1.11mmol), add them into a 50mL two-necked bottle in sequence, add DMF (20mL) under argon protection, react at 80℃ with stirring for about 6 hours, after the reaction is completed as monitored by thin layer chromatography, stop the reaction, transfer the solution to a single-mouth bottle, remove DMF with a rotary evaporator and an oil pump, dissolve in ethyl acetate, wash with saturated sodium chloride (10mL×3), discard the aqueous layer, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a crude product, which is then purified by column chromatography (elution system: petroleum ether: ethyl acetate) to obtain the target compound.

[0013] After preliminary cytotoxic activity screening, it was found that Figure 2 The compounds shown have no toxicity to PC12 cells (rat adrenal pheochromocytoma cells) and have a certain growth-promoting effect, which is similar to the control substance resveratrol. The in vitro Parkinson's disease cell model (PC12 cells were damaged by a certain concentration of hydrogen peroxide and 6-hydroxydopamine) was used to screen the Figure 2 The compounds shown in the present invention have been found to have a significant protective effect on PC12 cells, and the protective activity of some compounds is stronger than the classic antioxidant resveratrol (Res). In addition, the luciferase reporter gene experiment also proved that this type of compound has the function of activating Nrf2, and is much stronger than the classic Nrf2 activator tert-butylhydroquinone (t-BHQ) of the same concentration. Therefore, the novel coumarin compounds of the present invention can be used as effective Nrf2 activators and lead molecules for the development of neuroprotective and neurodegenerative disease drugs. The coumarin compounds described in the present invention have novel structures, simple synthesis processes, high product purity, and show strong protective effects on neural cells, and have excellent application prospects.

[0014] The above contents of the present invention are further described in detail below through specific implementation modes, but this should not be construed as limiting the present invention. DETAILED DESCRIPTION

[0015] Example 1: Target compound 1 (attached to the specification Figure 3 )

[0016] Preparation method of intermediate 2-(phenylsulfonyl)acetonitrile: phenylsulfonyl chloride (0.71mmol) is used as raw material, water is used as reaction solvent, sodium sulfite (0.18g, 1.42mmol) and sodium bicarbonate (0.12g, 1.42mmol) are added in sequence, and then the temperature is raised to 100°C for reflux reaction for 2 hours. After stopping the reaction, the reaction solution is concentrated under reduced pressure, and then the solid is directly subjected to the next step of reaction without purification, tetrahydrofuran is added under stirring, and chloroacetonitrile (0.05g, 0.71mmol) is added dropwise under argon protection, and the temperature is gradually raised to 60°C to start the reaction. After the reaction is completed by thin layer chromatography monitoring, the reaction is stopped. The reaction solution is concentrated under reduced pressure, washed with water, and filtered to obtain the intermediate 2-(phenylsulfonyl)acetonitrile.

[0017] Synthesis method of compound 1: Take the intermediate 2-(phenylsulfonyl)acetonitrile (0.55mmol), potassium fluoride (KF) (0.13g, 2.23mmol), 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (0.33g, 1.11mmol), add them to a 50mL two-necked bottle in sequence, add DMF (20mL) under argon protection, react at 80°C for about 6 hours under stirring, and stop the reaction after the reaction is completed by thin layer chromatography monitoring. The solution is transferred to a single-mouth bottle, and DMF is removed by rotary evaporator and oil pump. After dissolving in ethyl acetate, it is washed with saturated sodium chloride (10mL×3), the water layer is discarded, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain a crude product, which is then subjected to column chromatography (elution system is petroleum ether: ethyl acetate) to obtain the target compound. The reaction is shown in reaction formula 1 (attached to the specification) Figure 4 )

[0018] Compound 1. Yield: 51%; 1 H NMR (400MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.10 (d, 1H, J = 7.6Hz), 8.03 (d, 2H, J = 8Hz), 7.83-7.75 (m, 2H), 7.66 (t, 2H, J = 7.6Hz), 7.49 (t, 2H, J = 8Hz); 13 CNMR(100MHz,DMSO-d6)δ:155.0,154.7,149.2,138.5,135.6,134.2,131.4,129.2,128.5,126.6,125.3,117.5,116.4; MS-ESI m / z:287.03[M+H] + .

[0019] Example 2: Target compound 2 (attached to the specification Figure 5 )

[0020] The same as Example 1, only 2-methoxybenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 2. Yield: 38%; 1 H NMR (400MHz, DMSO-d6) δ: 9.15 (s, 1H), 8.18 (d, 1H, J = 7.6Hz), 8.02 (d, 1H, J = 7.6Hz), 7.82 (t, 1H,J=7.6Hz),7.72(t,1H,J=7.6Hz),7.51(t,2H,J=8.8Hz),7.25-7.20(m,2H),3.75(s,3H); 13 C NMR (100MHz, DMSO-d6) δ: 156.9, 154.8, 154.6, 149.6, 136.4, 135.5, 131.2, 130.6, 126.6, 125.7, 125.4, 120.5, 117.5, 116.5, 113.2, 56.3; MS-ESI m / z:317.04[M+H] + .

[0021] Example 3: Target compound 3 (attached to the specification Figure 6 )

[0022] The same as Example 1, only 4-methoxybenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 3. Yield: 47%; 1 H NMR (400MHz, DMSO-d6) δ: 9.10 (s, 1H), 8.08 (d, 1H, J = 7.6Hz), 7.95 (d, 2H, J = 8.8H z),7.79(t,1H,J=8Hz),7.48(t,2H,J=8Hz),7.17(d,2H,J=8.8Hz),3.86(s,3H); 13 C NMR (100MHz, DMSO-d6) δ: 163.7, 154.9, 154.7, 148.2, 135.4, 131.3, 131.2, 129.7, 127.3, 125.3, 117.5, 116.4, 114.5, 55.9; MS-ESI m / z:317.04[M+H] + .

[0023] Example 4: Target compound 4 (attached to the specification Figure 7 )

[0024] The same as Example 1, only 2-trifluoromethylbenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 4. Yield: 37%; 1H NMR (400MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.50 (d, 1H, J = 7.6Hz), 8.16 (d, 1H, J = 8Hz), 8.04-7.95 (m, 3H), 7.83 (t, 1H, J = 8Hz), 7.51-7.48 (m, 2H); 13 CNMR(100MHz,DMSO-d6)δ:155.5,155.1,150.0,137.2,136.4,135.4,134.6,133.7,132.0,129.0,1 29.0,128.9,128.8,127.9,127.6,127.2,126.9,126.8,125.9,124.6,121.9,117.8,117.0; MS-ESI m / z:355.02[M+H] + .

[0025] Example 5: Target compound 5 (attached to the specification Figure 8 )

[0026] The same as Example 1, except that 3-trifluoromethylbenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 5. Yield: 39%; 1 H NMR (400MHz, DMSO-d6) δ: 9.21 (s, 1H), 8.37 (d, 1H, J = 7.6Hz), 8.32 (s, 1H), 8.15 (d d,2H,J=8,21.6Hz),7.94(t,1H,J=8Hz),7.83(t,1H,J=8Hz),7.50(t,2H,J=8Hz); 13 C NMR(100MHz,DMSO-d6)δ:155.1,154.8,150.1,139.7,135.8,132.9,131.5,131.1,131.0,131.0,130. 9,130.8,130.2,129.9,129.6,129.2,125.8,125.4,125.4,125.3,124.7,121.9,117.5,116.5; MS-ESI m / z:355.02[M+H] + .

[0027] Example 6: Target compound 6 (attached to the specification Fig. 9 )

[0028] The same as Example 1, except that 4-trifluoromethylbenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 6. Yield: 34%; 1H NMR (400MHz, DMSO-d6) δ: 9.22 (s, 1H), 8.26 (d, 2H, J = 8.4Hz), 8.13 (d, 1H, J = 8Hz), 8.06 (d, 2H, J = 8.4Hz), 7.83 (t, 1H, J = 8Hz), 7.51 (t, 2H, J = 8Hz); 13 C NMR(100MHz,DMSO-d6)δ:155.1,154.8,150.0,142.5,135.8,133.8,133.5,131.5,1 29.7,126.4,126.4,126.4,126.3,125.8,125.3,124.7,122.0,117.5,116.5; MS-ESI m / z:355.02[M+H] + .

[0029] Example 7: Target compound 7 (attached to the specification Fig.10 )

[0030] The same as Example 1, only 3-methylbenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction products are as follows: Compound 7. Yield: 43%; 1 H NMR (400MHz, DMSO-d6) δ: 9.15 (s, 1H), 8.10 (d, 1H, J = 7.6Hz), 7.85-7.79 (m, 3H), 7.58-7.53 (m, 2H), 7.49 (t, 2H, J = 8.4Hz), 2.41 (s, 3H); 13 C NMR (100MHz, DMSO-d6)δ:155.0,154.6,149.1,139.0,138.5,135.5,134.8,131.3,129.1,128.4,126.6,125.7,125.3,117.5,116.4,20.8; MS-ESI m / z:301.05[M+H] + .

[0031] Example 8: Target compound 8 (attached to the specification Fig.11 )

[0032] The same as Example 1, only 4-methylbenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 8. Yield: 48%; 1H NMR (400MHz, DMSO-d6) δ: 9.13 (s, 1H), 8.09 (d, 1H, J = 7.6Hz), 7.91 (d, 2H, J = 7.6Hz), 7.80 (t, 1H, J = 8Hz), 7.50-7.45 (m, 4H), 2.41 (s, 3H); 13 CNMR(100MHz,DMSO-d6)δ:154.9,154.6,148.8,145.0,135.6,135.5,131.3,129.7,128.6,126.9,125.3,117.4,116.4,21.1; MS-ESI m / z:301.05[M+H] + .

[0033] Example 9: Target compound 9 (attached to the specification Fig.12 )

[0034] The same as Example 1, only 2-fluorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 9. Yield: 31%; 1 H NMR (400MHz, DMSO-d6) δ: 9.24 (s, 1H), 8.17 (d, 1H, J = 7.6Hz), 8.10 (t, 1H, J = 7.2Hz), 7.84 (t, 2H, J = 8Hz), 7.55-7.42 (m, 4H); 13 C NMR(100MHz,DMSO-d6)δ:160.0,157.5,155.1,154.6,149.7,137.4,137.3,135.9,135.1,1 31.5,131.5,126.2,126.2,126.0,125.4,125.2,125.1,117.5,117.4,117.3,116.5; MS-ESI m / z:305.02[M+H] + .

[0035] Example 10: Target compound 10 (attached to the specification Fig.13 )

[0036] The same as Example 1, only 3-fluorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 10. Yield: 34%; 1H NMR (400MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.10 (d, 1H, J = 7.6Hz), 7.89 (d, 1H, J = 7.6Hz) ,7.83(t,2H,J=8Hz),7.76-7.71(m,1H),7.67-7.62(m,1H),7.50(t,2H,J=7.6Hz); 13 C NMR(100MHz,DMSO-d6)δ:162.8,160.3,155.1,154.7,149.9,140.7,140.6,135.7,131.7,1 31.6,131.5,125.9,125.3,124.8,124.8,121.6,121.4,117.5,116.5,115.6,115.4; MS-ESI m / z:305.02[M+H] + .

[0037] Example 11: Target compound 11 (attached to the specification Fig.14 )

[0038] The same as Example 1, only 4-fluorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 11. Yield: 32%; 1 H NMR (400MHz, DMSO-d6) δ: 9.16 (s, 1H), 8.13-8.10 (m, 3H), 7.82 (t, 1H, J = 7.6Hz), 7.54-7.47 (m, 4H); 13 C NMR(100MHz,DMSO-d6)δ:166.6,164.1,155.0,154.7,149.2,135.6,134.8,1 34.8,132.1,132.0,131.4,126.5,125.3,117.5,116.6,116.4,116.4;MS-ESI m / z:305.02[M+H] + .

[0039] Example 12: Target compound 12 (attached to the specification Fig.15 )

[0040] The same as Example 1, only 2-chlorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 12. Yield: 30%; 1H NMR (400MHz, DMSO-d6) δ: 9.30 (s, 1H), 8.30 (d, 1H, J = 8Hz), 8.18 (d, 1H, J = 7.6Hz), 7.85 (t,1H,J=8Hz),7.79(t,1H,J=7.6Hz),7.70(dd,2H,J=8,18.4Hz),7.53(t,2H,J=8Hz); 13 C NMR (100MHz, DMSO-d6)δ:155.0,154.5,151.0,136.0,135.4,132.6,131.9,131.5,131.3,128.0,125.5,125.2,117.3,116.6; MS-ESI m / z:320.99[M+H] + .

[0041] Example 13: Target compound 13 (attached to the specification Fig.16 )

[0042] The same as Example 1, only 3-chlorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 13. Yield: 34%; 1 H NMR (400MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.10 (d, 1H, J = 7.2Hz), 8.02 (t, 2H, J = 7.6Hz), 7.84 (dd, 2H, J = 7.6, 14.4Hz), 7.71 (t, 1H, J = 8Hz), 7.50 (t, 2H, J = 8Hz); 13 C NMR (100MHz, DMSO-d6) δ: 155.1, 154.8, 150.0, 140.4, 135.7, 134.2, 133.7, 131.5, 131.2, 128.0, 127.3, 125.9, 125.3, 117.5, 116.5; MS-ESI m / z:320.99[M+H] + .

[0043] Example 14: Target compound 14 (attached to the specification Fig.17 )

[0044] The same as Example 1, only 4-chlorobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 14. Yield: 38%; 1H NMR (400MHz, DMSO-d6) δ: 9.16 (s, 1H), 8.10 (d, 1H, J = 7.6Hz), 8.04 (d, 2H, J = 8.4Hz), 7.82 (t, 1H, J = 8Hz), 7.75 (d, 2H, J = 8.4Hz), 7.49 (t, 2H, J = 7.6Hz); 13 C NMR (100MHz, DMSO-d6)δ:155.0,154.7,149.4,139.4,137.3,135.7,131.4,130.6,129.4,126.3,125.3,117.5,116.4; MS-ESI m / z:320.99[M+H] + .

[0045] Example 15: Target compound 15 (attached to the specification Fig.18 )

[0046] The same as Example 1, only 2-bromobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 15. Yield: 33%; 1 H NMR (400MHz, DMSO-d6) δ: 9.31 (s, 1H), 8.34 (d, 1H, J = 8Hz), 8.17 (d, 1H, J = 7.6Hz), 7 .88-7.84(m,2H),7.76(t,1H,J=7.6Hz),7.67(t,1H,J=7.6Hz),7.53(t,2H,J=8Hz); 13 C NMR (100MHz, DMSO-d6)δ:155.0,154.5,151.4,137.0,136.0,135.9,135.4,132.9,131.5,128.5,125.5,124.9,119.8,117.2,116.6; MS-ESI m / z:363.96[M+H] + .

[0047] Example 16: Target compound 16 (attached to the specification Fig.19 )

[0048] The same as Example 1, only 3-bromobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 16. Yield: 32%; 1H NMR (400MHz, DMSO-d6) δ: 9.17 (s, 1H), 8.16 (s, 1H), 8.10 (d, 1H, J = 7.6Hz), 8.05 (d, 1H, J = 7 .6Hz), 7.98 (d, 1H, J = 8Hz), 7.82 (t, 1H, J = 7.6Hz), 7.64 (t, 1H, J = 8Hz), 7.50 (t, 2H, J = 8Hz); 13 C NMR (100MHz, DMSO-d6) δ: 155.1, 154.8, 149.9, 140.6, 137.1, 135.7, 131.4, 131.4, 130.8, 127.7, 125.9, 125.3, 121.9, 117.5, 116.5; MS-ESI m / z:363.96[M+H] + .

[0049] Example 17: Target compound 17 (attached to the specification Fig. 20 )

[0050] The same as Example 1, only 4-bromobenzenesulfonyl chloride was used instead of benzenesulfonyl chloride as the starting material. The test data of the reaction product are as follows: Compound 17. Yield: 39%; 1 H NMR (400MHz, DMSO-d6) δ: 9.16 (s, 1H), 8.10 (d, 1H, J = 8Hz), 7.96 (d, 2H, J = 8.4Hz), 7.89 (d, 2H, J = 8.4Hz), 7.82 (t, 1H, J = 8Hz), 7.49 (t, 2H, J = 8Hz); 13 C NMR (100MHz, DMSO-d6)δ:155.0,154.7,149.4,137.8,135.7,132.3,131.4,130.6,128.5,126.2,125.3,117.5,116.5; MS-ESI m / z:363.96[M+H] + .

[0051] Example 18: Target compound 18 (attached to the specification Fig.21 )

[0052] The same as Example 1, only 2-naphthalenesulfonyl chloride was used as the starting material instead of benzenesulfonyl chloride. The test data of the reaction products are as follows: Compound 18. Yield: 45%; 1H NMR (400MHz, DMSO-d6) δ: 9.23 (s, 1H), 8.76 (s, 1H), 8.25 (d, 1H, J = 8Hz), 8.16 (dd, 2H, J = 8, 15.2 Hz), 8.09 (d, 1H, J = 8Hz), 8.00 (d, 1H, J = 8.8Hz), 7.83-7.69 (m, 3H), 7.49 (dd, 2H, J = 8, 15.2Hz); 13 C NMR(100MHz,DMSO-d6)δ:155.0,154.7,149.2,135.6,134.9,131.6,131.4,130. 5,129.6,129.6,129.2,127.9,127.7,126.6,125.3,123.1,117.5,116.4;MS-ESI m / z:337.05[M+H] + .

[0053] Example 19: Target compound 19 (attached to the specification Fig. 22 )

[0054] The same as Example 1, except that 1-naphthalenesulfonyl chloride was used as the starting material instead of benzenesulfonyl chloride. The test data of the reaction products are as follows: Compound 19. Yield: 38%; 1 H NMR (400MHz, DMSO-d6) δ: 9.53 (s, 1H), 8.54 (t, 2H, J = 8Hz), 8.39 (d, 1H, J = 8Hz), 8.16 (q, 2H, J =7.6Hz),7.86-7.78(m,2H),7.72-7.64(m,2H),7.51(t,1H,J=7.6Hz),7.44(d,1H,J=8.4Hz); 13 C NMR(100MHz,DMSO-d6)δ:154.9,154.5,149.5,135.9,135.7,133.6,132.6,132.5,1 31.4,129.5,128.8,127.5,126.9,126.9,125.4,124.8,123.3,117.4,116.4;MS-ESI m / z:337.05[M+H] + .

[0055] Example 20: Target compound 20 (attached to the specification Fig.23 )

[0056] The same as Example 1, only 2-thiophenesulfonyl chloride was used as the starting material instead of benzenesulfonyl chloride. The test data of the reaction products are as follows: Compound 20. Yield: 32%; 1H NMR (400MHz, DMSO-d6) δ: 9.12 (s, 1H), 8.18 (d, 1H, J = 4.8Hz), 8.09 (d, 1H, J = 7.6Hz), 7 .94(d,1H,J=3.6Hz),7.81(t,1H,J=8Hz),7.48(t,2H,J=8Hz),7.29(t,1H,J=4.4Hz); 13 C NMR (100MHz, DMSO-d6) δ: 154.9, 154.6, 148.3, 138.9, 136.8, 136.2, 135.6, 131.4, 128.2, 127.2, 125.3, 117.4, 116.4; MS-ESI m / z: 324.11[M+MeOH+H] + . Experimental methods and results of cytotoxic activity, neuroprotective activity and luciferase reporter gene of compounds 1-20

[0057] (1) Cell culture: PC12 cells are rat adrenal pheochromocytoma cells, which are derived from the Lanzhou Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. When the cells are cultured in vitro, in order to make their growth conditions similar to their in vivo growth conditions, the environmental conditions of in vivo growth must be simulated in vitro. The necessary conditions for cell survival are provided, such as DMEM medium (containing 10% fetal bovine serum, 1% penicillin-streptomycin, 2mM glutamine) in a CO2 cell culture incubator with 5% CO2, 37°C and 95% humidity.

[0058] (2) MTT assay: Digested PC12 cells were plated at 1×10 4 Cells / well were planted in a 96-well plate and cultured for 24 hours. Then, the cells were treated with compounds at different concentrations and incubated for 24 hours. Then, 0.5 mg / mL MTT was added and the 96-well plate was placed in a CO2 cell culture incubator for 4 hours to generate blue-purple formazan. Finally, 100 μL of a triple solution (10% SDS, 5% isobutanol, and 0.1% hydrochloric acid) was added to dissolve overnight. The absorbance value was read at 570 nm using an ELISA reader. The results of cytotoxic activity are shown in the attached manual. Fig.24 A.

[0059] (3) Experiment on oxidative damage of PC12 cells by hydrogen peroxide (H2O2) or 6-hydroxydopamine (6-OHDA): PC12 cells were incubated at 1×10 4Cells / well were seeded in a 96-well plate and incubated with different concentrations of compounds for 24 hours. The medium containing the compound was then discarded and medium containing hydrogen peroxide (600 μM) or 6-hydroxydopamine (500 μM) and 10% fetal bovine serum was added for incubation for 1.5 hours and 5.5 hours respectively. The cell survival rate was determined by MTT assay. Neuroprotective activity is shown in the attached manual Fig.24 B and C.

[0060] (4) Luciferase reporter gene experiment: pARE-luc plasmid was transformed and amplified by E. coli, extracted by high-purity medium kit for later use, and the cells to be transfected were inoculated in 6-well plates. When the cells grew to about 50%, the pARE-luc plasmid was transferred into PC12 cells using transfection reagent. After 24 hours of drug incubation, the cells were collected and then lysate (1% Triton X-100, 25mM Glycylglycine, 15mM MgSO4, 4mM EGTA, 1mM DTT) was added. The cells were crushed with an ultrasonic cell crusher, and the protein quantification was 2mg / mL. 200μL of detection solution (100μM luciferin, 25mM Glycylglycine, 15mM K3PO4, 15mM MgSO4, 4mM EGTA, 2mM ATP, 1mM DTT) and 10μL of protein supernatant were added to each well, and the bioluminescence was finally measured with a fluorescence meter. Luciferase reporter gene activity is shown in the instruction manual. Fig.25 .

[0061] The cytotoxicity test on PC12 cells showed that all 20 compounds had no cytotoxicity to the cells (see Appendix Fig.24 A). Neuroprotective activity experiments have shown that more than half of the compounds have significant protective effects on PC12 cells damaged by hydrogen peroxide or 6-hydroxydopamine (see Appendix Fig.24 B and C), and the protective effect of some compounds was much higher than that of resveratrol (Res), among which compound 20 had the highest protective activity, and one of its mechanisms of action was to activate Nrf2 (see Appendix Fig.25 ). In summary, compound 20 has great application potential as an Nrf2 activator for the development of neuroprotective drugs or drugs for neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 This is a general synthetic route for the target compound.

[0063] Figure 2 The following are the general chemical structural formulas of twenty target compounds containing a coumarin skeleton.

[0064] Figure 3is the specific chemical structural formula of target compound 1.

[0065] Figure 4 Reaction formula 1 is the specific chemical reaction process for synthesizing target compound 1.

[0066] Figure 5 is the specific chemical structural formula of target compound 2.

[0067] Figure 6 is the specific chemical structural formula of target compound 3.

[0068] Figure 7 is the specific chemical structural formula of target compound 4.

[0069] Figure 8 is the specific chemical structural formula of target compound 5.

[0070] Fig. 9 is the specific chemical structural formula of the target compound 6.

[0071] Fig.10 is the specific chemical structural formula of target compound 7.

[0072] Fig.11 is the specific chemical structural formula of the target compound 8.

[0073] Fig.12 is the specific chemical structural formula of the target compound 9.

[0074] Fig.13 is the specific chemical structural formula of the target compound 10.

[0075] Fig.14 is the specific chemical structural formula of the target compound 11.

[0076] Fig.15 is the specific chemical structural formula of the target compound 12.

[0077] Fig.16 is the specific chemical structural formula of the target compound 13.

[0078] Fig.17 is the specific chemical structural formula of the target compound 14.

[0079] Fig.18 is the specific chemical structural formula of target compound 15.

[0080] Fig.19 is the specific chemical structural formula of the target compound 16.

[0081] Fig. 20 is the specific chemical structural formula of the target compound 17.

[0082] Fig.21 is the specific chemical structural formula of the target compound 18.

[0083] Fig. 22 is the specific chemical structural formula of the target compound 19.

[0084] Fig.23 is the specific chemical structural formula of the target compound 20.

[0085] Fig.24 The biological activity diagrams of all twenty target compounds, namely (A) cytotoxic activity of the target compounds on PC12 cells; (B and C) protective activity of the target compounds on PC12 cells.

[0086] Fig.25 is the luciferase reporter gene activity of target compound 20.

Claims

1. A coumarin compound, characterized in that The compound has the chemical structure shown in formula (I): In the structural formula (I), the substituent R is selected from 2-thienyl.

2. The method for preparing a coumarin compound according to claim 1, characterized in that 0.55mmol of 2-(2-thienylsulfonyl)acetonitrile and 1.11mmol of 2-(trimethylsilyl)phenyl trifluoromethanesulfonate were dissolved in N,N-dimethylformamide, and 2.23mmol of potassium fluoride was added. The reaction was carried out at 80°C for 6 hours, and the reaction was detected by thin layer chromatography. After the reaction was complete, the solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography with petroleum ether:ethyl acetate as the elution system to obtain the target compound.

3. A coumarin compound according to claim 1, characterized in that It can be used in the preparation of medicines for preventing or treating neurodegenerative diseases, and the specific disease is Parkinson's disease.